By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Researchers detail new data in Prostate Cancer. According to news reporting from Lexington, Kentucky, by NewsRx journalists, research stated, "Previous studies demonstrated that proteasome inhibition sensitizes TRAIL resistant prostate cancer cells to TRAIL-mediated apoptosis via stabilization of the active p18 subunit of caspase-8. The present study investigated the impact of proteasome inhibition on caspase-8 stability, ubiquitination, trafficking, and activation in cancer cells."
The news correspondents obtained a quote from the research from the University of Kentucky College of Medicine, "Using caspase-8 deficient neuroblastoma (NB7) cells for reconstituting non-cleavable mutant forms of caspase-8, we demonstrated that the non-cleavable forms of caspase-8 are capable of inducing apoptosis comparably to wild-type caspase-8, in response to proteasome inhibitor and GST-TRAIL. Moreover in the LNCaP human prostate cancer cells, caspase-8 polyubiquitination occurs after TRAIL stimulation and caspase-8 processing. Subcellular fractionation analysis revealed caspase-8 activity in both cytosol and plasma membrane fractions in both NB7 reconstituted caspase-8 cell lines, as well the LNCaP prostate cancer cells. The present results suggest that caspase-8 stabilization through proteasome inhibition leads to reactivation of the extrinsic pathway of apoptosis and identify E3 ligase mediating caspase-8 polyubiquitination, as a novel molecular target."
According to the news reporters, the research concluded: "Inhibition of this E3 ligase in combination with TRAIL towards restoring apoptosis signaling activation may have potential therapeutic significance in resistant tumors."
For more information on this research see: Proteasomal regulation of caspase-8 in cancer cell apoptosis. Apoptosis, 2013;18(6):766-76. Apoptosis can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Apoptosis - www.springerlink.com/content/1360-8185/)
Our news journalists report that additional information may be obtained by contacting M.V. Fiandalo, Dept. of Molecular and Cellular Biochemistry and the Markey Cancer Center, University of Kentucky College of Medicine, Combs Cancer Research Building, 306, 800 Rose Street, Lexington, KY 40536, United States (see also Prostate Cancer).
Publisher contact information for the journal Apoptosis is: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Kentucky, Caspases, Oncology, Lexington, Apoptosis, Therapeutics, United States, Prostate Cancer, Peptide Hydrolases, Cancer Gene Therapy, Prostatic Neoplasms, Enzymes and Coenzymes, Cysteine Endopeptidases, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.